Ótologie Tinnitus Care Ltd. teams up with British Tinnitus Association to provide free assessments to mark Tinnitus Week 2022
Ótologie is proud to sponsor BTA Tinnitus Week
DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Specialist tinnitus service, Ótologie Tinnitus Care is offering free assessments to people living with tinnitus to mark its sponsorship of the British Tinnitus Association's Tinnitus Week, which runs from 7th – 13th February 2022.
Anyone who books a tinnitus assessment with Ótologie, from 7th – 13th February, will get the assessment, which normally costs £85, free of charge.
Owned by medical devices company, Neuromod Devices Ltd, Ótologie is a specialist healthcare service for people living with tinnitus, in the UK and throughout Europe, to avoid waiting lists and give them immediate access to treatment for their tinnitus.
Tinnitus, commonly known as "ringing in the ears" affects between 10 and 15% of the global adult population[i] and the BTA estimates that more than seven million people suffer from this condition in the UK alone[ii].
A recent poll by Neuromod found that more than three quarters of people living from tinnitus in the UK have never received any treatment for their condition.
The research, which polled 251 people with tinnitus across the UK, found that 76.1% of respondents have never used any form of tinnitus treatment. It also revealed that 67.7% of those polled don't feel adequately informed about tinnitus.
For those who have sought treatment for their tinnitus, a consultation with an ENT is commonplace. However, COVID-19 continues to impact the health service's ability to provide care to people with tinnitus. As of November 2021, the most recently available statistics from the NHS, 45% of people on referral to treatment waiting lists for ENTs had been waiting for more than 18 weeks[iii].
A dedicated tinnitus assessment includes more than a hearing test, as this condition affects the auditory, attentional, and emotional areas of a patient's brain. The free assessment is conducted by one of Ótologie's audiologists and includes an evaluation of tinnitus using clinical standards designed specifically for the condition, a full medical evaluation, a hearing test and, based on the results of all these diagnostics, a treatment recommendation.
This allows the audiologist to fully understand how the tinnitus is affecting every individual patient's life.
Speaking on this initiative, Ms. Lia Bresnihan, Managing Director at Ótologie said: "The tinnitus experience varies greatly from person-to-person. The condition affects the auditory, attentional, and emotional areas of your brain. That's why it is so important to have an assessment from a qualified audiologist if you have been suffering from tinnitus for more than three months. People who struggle with tinnitus often suffer in silence as they may think that because there is no cure for tinnitus, that there is no treatment that will help them. By offering free assessments, we are hoping to inform patients as best we can about their condition and to empower them to do something about that annoying ringing in their ears."
To avail of a free tinnitus assessment visit www.otologie.com/bta, book a call and use the promotional code BTAWEEK. Tinnitus assessments normally cost a patient £85. The assessment, which a patient can choose at a day and time that suits them, will be done via a video call.
Furthermore, to mark Tinnitus Week, Ótologie is also hosting a free webinar, 'Living with tinnitus: What are the treatment options?', which will take place on Thursday 10th February at 1pm.
This session, which will be delivered by Ótologie's specialist audiologists Helen MacMahon and Clodagh Kelly, will help attendees to better understand their tinnitus; provide practical advice for how to best manage tinnitus; and detail the various treatment options available to patients.
The webinar is free of charge and limited spaces can be booked at www.otologie.com/webinar-living-with-tinnitus/.
Ms. Bresnihan added, "We are delighted to partner with the British Tinnitus Association as a sponsor of their Tinnitus Week. The BTA's mission is to drive progress towards a cure and to deliver excellent support to help people living with tinnitus. This aligns with our mission at Ótologie to provide groundbreaking tinnitus care that improves the lives of many. Also, I would encourage anyone who is looking to learn more about their tinnitus, or if they have a loved one or friend with tinnitus and they just want to learn more about the condition, to sign up for our free webinar on Thursday 10th February."
About Ótologie
Ótologie is an effective, patient-centred service that provides ground-breaking tinnitus care to improve the lives of people living with this condition every day and it has been established to address the growing healthcare need for people with tinnitus.
Its specialist audiologists and psychotherapists, have extensive experience treating tinnitus patients with the latest evidence-based treatments. They follow clinical best practices to assess each patient and recommend a personalised treatment plan from treatment options such as of Lenire, tinnitus therapy (CBT), or hearing aids for tinnitus. Combining these treatment options and the company's technology-led platform, which offers next day appointments.
In 2021, Neuromod piloted a telehealth service to treat tinnitus patients in Ireland and throughout Europe. Due to the success of the pilot, which allowed patients to progress to treatment within days of contacting the service and avoid waiting lists for public ENT appointments, Neuromod established Ótologie, early in 2022, to provide quick access to tinnitus care from qualified healthcare professionals.
Ótologie streamlines the typical healthcare journey for tinnitus patients, offering them next day appointments which they can attend online or in-clinic. Its team of audiologists and therapists, specifically trained in treating tinnitus, have extensive experience treating patients with evidence-based treatments.
For more information please contact:
Robert Magee
Senior Communications Manager,
Neuromod Devices
robert.magee@neuromoddevices.com / +353 87 670 6826
Notes to Editor:
Ótologie's treatment options for tinnitus
- Lenire - Lenire, a non-invasive bimodal neuromodulation device, has been proven in large-scale clinical trials to soothe the symptoms of tinnitus. Lenire delivers mild electrical pulses to the tongue combined with sound played through headphones to drive long-term changes, or neuroplasticity, in the brain to treat tinnitus.
- Tinnitus Therapy - Tinnitus Therapy is a form of psychotherapy which aims to change a patient's perception of their tinnitus and minimise its impact on their life.
- Hearing Aids for Tinnitus - Hearing loss is one of the most common causes of tinnitus and improving a patients hearing can improve their symptoms. Ótologie offers a range of hearing aids, and ongoing support.
About Neuromod Devices Limited
Founded in 2010, Neuromod Devices Ltd is a medical technology company headquartered in Dublin, Ireland. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The lead application of Neuromod's technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. Neuromod's tinnitus treatment device, Lenire is currently available in Ireland and throughout Europe. For more information visit www.neuromoddevices.com.
About Fountain Healthcare Partners
Fountain Healthcare Partners is a life science venture capital fund with offices in Dublin and New York. Founded in 2008, Fountain is Ireland's largest dedicated life science venture capital fund with more than €300 million under management. Fountain invests in entrepreneurs and companies with disruptive technologies or products that have a clear pharmacoeconomic benefit and a defined pathway to commercialisation, value enhancement and exit. Fountain typically leads or co-leads its investments and has sourced private and public deals from start-ups, corporate spin-outs and turnaround situations.
References:
[i] Baguley D, McFerran D, Hall D. Tinnitus. Lancet 2013:382 (9904):1600-7
[ii] British Tinnitus Association - https://www.tinnitus.org.uk/blog/more-people-living-with-tinnitus-than-previously-thought
[iii] NHS - https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2022/01/Nov21-RTT-SPN-publication.pdf
Share this article